All In Biotech

Drug Trial Radar · NCT04021368

RVU120 in Patients With Acute Myeloid Leukemia or High-risk Myelodysplastic Syndrome

A Phase Ib Study of RVU120 (SEL120) in Patients With Acute Myeloid Leukemia or High-risk Myelodysplastic Syndrome

Last checked: Nov 19, 2026Latest source record: Sep 18, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Terminated

Status

Terminated

Enrollment

51

Actual

Start

Sep 4, 2019

Primary completion

May 21, 2024

Study completion May 21, 2024

Sponsor

Lead sponsor
Ryvu Therapeutics SAIndustry
Sponsor type
Industry
First posted
Jul 16, 2019

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This first-in-human study will evaluate RVU120 (SEL120), a novel small molecule CDK8/19 inhibitor, in patients with Acute Myeloid Leukemia (AML) or High-risk Myelodysplastic Syndrome (HR-MDS), in terms of selection of the recommended dose for further clinical development and assessment of safety, tolerability, preliminary anti-leukemic activity, as well as pharmacokinetic and pharmacodynamic profiles.

Conditions

  • Acute Myeloid Leukemia
  • High-risk Myelodysplastic Syndrome

Interventions

  • RVU120(SEL120)Drug

    RVU120(SEL120) will be administered as a single oral dose every other day (q.o.d.) for a total of 7 doses i.e. on Days 1, 3, 5, 7, 9, 11 and 13, in a 3-week treatment cycle.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Recommended dose (RD)Time frame: Up to 2 years
  2. Incidence of Adverse Events (Safety and Tolerability)Time frame: Up to 2 years

Locations

10 sites in 2 countries. Site status is shown where the registry gives one.

  • Sylvester Comprehensive Cancer Center, University of Miami Hospital and Clinics

    Miami, Florida

  • Northside Hospital

    Atlanta, Georgia

  • Washington University School of Medicine

    St Louis, Missouri

  • Tennessee Oncology

    Nashville, Tennessee

  • MD Anderson Cancer Center

    Houston, Texas

  • Uniwersyteckie Centrum Kliniczne

    Gdansk, Poland

  • MICS Centrum Medyczne Toruń

    Torun, Poland

  • Instytut Hematologii i Transfuzjologii

    Warsaw, Poland

  • Dolnośląskie Centrum Onkologii, Pulmonologii i Hematologii

    Wroclaw, Poland

  • Świętokrzyskie Centrum Onkologii, Klinika Hematologii i Transplantacji Szpiku

    Kielce, Świętokrzyskie Voivodeship, Poland

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.